Natural products industry companies share overviews on the latest science on their branded ingredients and formulations to ...

By blocking dopamine-1 receptors, ecopipam is expected to reduce the repetitive and compulsive behaviors seen in Tourette syndrome.

Galcanezumab provided greater reductions in migraine frequency, resulting in a shift from chronic to episodic migraine over a 12-month period compared with placebo.

Magnesium and melatonin are commonly used as sleep aids, though their effects are generally modest. Learn how they work and ...

About REFOCUS-ALZ REFOCUS-ALZ (NCT05026177) is a Phase 3 trial designed as a multi-center, double-blinded, placebo-controlled, randomized parallel group study to evaluate the safety and efficacy of ...

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic ...

Two of the four phase 2/3 multicenter, randomized double-blind studies showed encouraging signals, which means they’re now moving to phase 3 trials. The new results illustrate exactly what a ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering ...

Biodexa Pharmaceuticals (BDRX) announced the appointment of Precision for Medicine as the clinical research organization, CRO, to conduct the ...

EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...